


CLINICAL TRIAL PHASE 2B For Patients with Chronic Kidney Disease Stage 4



<https://www.kibowtx.com/pipeline/#KT-301>

Study Drug and Purpose: US-APR2020 is a Live Biotherapeutic Product (LBP) intended to restore the gut microbiome balance to improve the removal of uremic toxins in the bowel in CKD patients. This Phase 2b study is to evaluate the safety and efficacy of the probiotics in the management of patients with CKD Stage IV.

Progress: 23 of the 26 clinical trial sites are actively enrolling participants, with 240 of 630 participants already enrolled. The goal is to validate the delay of dialysis on CKD-IV patients in conjunction with their individual standard of care with the addition of the US-APR2020 investigative product.



Kibow Biotech's principal mission is to offer affordable, accessible, and orally administered nutritional and health supplements primarily for failing kidney function.

Kibow is a pioneer in modulating the gut microbiome with its patented and proprietary formulations. Our platform technology is known as "Enteric®/Intestinal Dialysis", which metabolizes various uremic toxins that diffuse from the circulating blood into the bowel in patients with chronic kidney disease.